**EQUITY RESEARCH - ANALYST MEETING** 



# BANGKOK CHAIN HOSPITAL

**BCH TB** 

THAILAND / HEALTH CARE SERVICES



# Key takeaways from analyst meeting

# TARGET PRICE THB22.00 CLOSE THB15.40 UP/DOWNSIDE +42.9% TP vs CONSENSUS +0.8%

# **Highlights**

- We have slightly positive feedback from the 2Q24 analyst meeting based on the market's two concerns that are likely to become clearer this year.
- First concern over SSO: The Private Hospital Association will negotiate with the SSO before signing contracts for next year (by October). They plan to request the SSO to increase the global budget for high-cost care (RW>2) and guarantee the reimbursement rate (ideally 12,000/RW).
- Second concern over Kuwait's GOP list: Kuwait is expected to announce the list of hospitals that will receive patients with a Guarantee of Payment (GOP) by the end of this year. BCH is confident of being among the three hospitals selected by the Kuwaiti government.
- BCH may book a reimbursement rate of 7,200/RW in 4Q24 to avoid a provision in the following year.
- BCH has received the final SSO chronic disease payment for 2023 and is expected to record an additional gain of THB60-70m in 3Q24 (vs THB54m gain in 4Q23).
- Management has revised the 2024 revenue target down from double-digit to high single-digit growth. However, this implies that 2H24 revenue should accelerate and improve compared to 1H24 (+3% y-y).
- Hospitals in the group have increased treatment fees by an average of 3-5% since August.
- ARI Radiation Oncology Clinic will start operating in September and is expected to reduce the cost of referring cancer patients to government hospitals by THB60m/year. BCH expects the Clinic to turn profitable by the first year of operation.

#### Recommendation

BCH's share price has plunged by 22% over the past three months. We believe it has already priced in two major concerns (SSO's high-cost care payment rate and Kuwait's GOP list). We suggest investors accumulate the stock to capture the likely positive outcome of these concerns, or keep the stock on the radar as the risk/reward ratio is gearing to positive, in our view. BCH trades at an attractive valuation of 24x 2024E P/E.

## **KEY STOCK DATA**

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	11,729	12,393	13,659	15,055
Net profit	1,406	1,605	1,875	2,171
EPS (THB)	0.56	0.64	0.75	0.87
vs Consensus (%)	-	(1.4)	(2.3)	3.8
EBITDA	2,802	3,073	3,469	3,899
Recurring net profit	1,406	1,605	1,875	2,171
Core EPS (THB)	0.56	0.64	0.75	0.87
EPS growth (%)	(53.7)	14.1	16.8	15.8
Core P/E (x)	27.3	23.9	20.5	17.7
Dividend yield (%)	3.2	2.3	2.3	2.7
EV/EBITDA (x)	13.9	12.4	10.6	9.2
Price/book (x)	3.0	2.9	2.7	2.5
Net debt/Equity (%)	(4.4)	(10.7)	(17.5)	(23.9)
ROE (%)	11.2	12.4	13.6	14.6



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(10.5)	(21.8)	(21.0)
Relative to country (%)	(14.3)	(22.0)	(9.6)
Mkt cap (USD m)			1,130
3m avg. daily turnover (USD m)			5.5
Free float (%)			44
Major shareholder	Chaleri	m Harnpha	nich (33%)
12m high/low (THB)		2	3.80/14.80
Issued shares (m)			2,493.75

Sources: Bloomberg consensus; FSSIA estimates



**Teerapol Udomvej, CFA**Fundamental Investment Analyst on Securities; License no. 080523
teerapol.udo@fssia.com, +66 2646 9969

# Recap: 2Q24 results review

BCH reported a 2Q24 core profit of THB277m (-3% y-y, -13% q-q). In this quarter, BCH booked an SSO revenue reversal of THB81m (THB60m net tax) following the insufficient budget for high-cost care (RW>=2), which was revised down to THB7,200/RW from THB12,000/RW for treatments during Oct to Dec-23. Excluding this item, BCH's core profit would be THB337m (+19% y-y), in line with our estimate.

Revenue was flat y-y, as cash patient revenue was flat y-y. OPD revenue grew by 12% y-y, driven by the Thai patient volume. However, IPD revenue fell 13% y-y due to a decrease in Middle East patients during the Ramadan period and the slowdown of Kuwaiti patients following the Kuwait government's policy to cut payment guarantees for citizens seeking treatment overseas.

SSO revenue was flat y-y. Excluding the SSO revenue reversal, total revenue and SSO revenue would grow by 3% y-y and 9% y-y, respectively.

The EBITDA margin was flat y-y at 22%. Excluding the SSO revenue reversal, the EBITDA margin would improve to 24%.

1H24 core profit of THB596m accounted for 37% of our 2024 core profit forecast of THB1.6b.

Exhibit 1: BCH - 2Q24 result summary

	2Q23	3Q23	4Q23	1Q24	2Q24	Cha	ange	2023	2024E	Chg.
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Sales	2,849	3,175	3,032	2,844	2,857	0	0	11,729	12,393	ć
COGS (incl. depreciation)	(1,989)	(2,098)	(2,094)	(2,044)	(2,112)	3	6	(8,116)	(8,628)	6
Gross profit	860	1,077	938	801	744	(7)	(13)	3,613	3,765	4
SG&A	(495)	(470)	(392)	(376)	(388)	3	(22)	(1,755)	(1,673)	(5)
Operating profit	365	607	547	425	356	(16)	(2)	1,859	2,092	13
Net other income	28	26	40	23	28	22	(1)	119	120	1
Interest expense	(24)	(30)	(13)	(11)	(13)	14	(48)	(95)	(53)	(45)
Pretax profit	369	602	574	437	372	(15)	1	1,882	2,159	15
Income Tax	(86)	(135)	(114)	(87)	(70)	(20)	(19)	(405)	(432)	7
Associates	2	0	(0)	0	(0)			1	1	n/a
Minority interest	(1)	(27)	(32)	(31)	(25)	(20)	nm	(73)	(123)	70
Core profit	284	441	427	319	277	(13)	(3)	1,406	1,605	14
Extraordinaries, GW & FX	0	0	0	0	0					
Reported net profit	284	441	427	319	277	(13)	(3)	1,406	1,605	14
Outstanding shares (m)	2,494	2,494	2,494	2,494	2,494	0	0	2,494	2,494	C
Core EPS (THB)	0.11	0.18	0.17	0.13	0.11	(13)	(3)	0.56	0.64	14
EPS (THB)	0.11	0.18	0.17	0.13	0.11	(13)	(3)	0.56	0.64	14
COGS (excl. depreciation)	1,755	1,861	1,858	1,803	1,871	4	7	7,172	7,646	7
Depreciation	234	237	236	240	242	1	3	944	982	4
EBITDA	627	869	823	688	626	(9)	(0)	2,922	3,193	9
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	30	34	31	28	26	(2)	(4)	31	30	(0)
SG&A/Revenue	17	15	13	13	14	0	(4)	15	14	(1)
EBITDA margin	22	27	27	24	22	(2)	(0)	24	25	1
Net profit margin	10	14	14	11	10	(2)	(0)	12	13	1
Operating stats	(y-y %)									
Cash-OPD revenue growth	(21)	(22)	8	14	9					
Cash-OPD volume growth	(47)	(23)	10	10						
Cash-OPD revenue per head growth	49	1	0	3						
Cash-IPD revenue growth	13	4	9	(1)	(13)					
Cash-IPD volume growth	(56)	51	23	5						
Cash-IPD revenue per head growth	25	(10)	(5)	(6)						
SSO revenue growth	16	15	12	9	0					
SSO registered member ('000)	1,012	1,011	1,014	1,015						
SSO registered member growth	4	2	0	0						
SSO revenue per head growth	(64)	(19)	7	8						

Sources: BCH; FSSIA estimates

# **Financial Statements**

Bangkok Chain Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	18,827	11,729	12,393	13,659	15,055
Cost of goods sold	(12,772)	(8,116)	(8,628)	(9,405)	(10,271)
Gross profit	6,055	3,613	3,765	4,254	4,783
Other operating income	-	-	-	-	-
Operating costs	(1,946)	(1,755)	(1,673)	(1,817)	(1,972)
Operating EBITDA	5,059	2,802	3,073	3,469	3,899
Depreciation	(950)	(944)	(982)	(1,032)	(1,088)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	4,109	1,859	2,092	2,437	2,811
Net financing costs	(148)	(77)	(37)	(35)	(27)
Associates	0	1	1	1	1
Recurring non-operating income	84	102	106	111	117
Non-recurring items	0	0	0	0	0
Profit before tax	4,046	1,883	2,160	2,513	2,901
Тах	(888)	(405)	(432)	(502)	(580)
Profit after tax	3,157	1,479	1,728	2,011	2,321
Minority interests	(118)	(73)	(123)	(136)	(150)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	3,039	1,406	1,605	1,875	2,171
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	3,039	1,406	1,605	1,875	2,171
Per share (THB)					
Recurring EPS *	1.22	0.56	0.64	0.75	0.87
Reported EPS	1.22	0.56	0.64	0.75	0.87
DPS	1.40	0.50	0.35	0.35	0.41
Diluted shares (used to calculate per share data)	2,494	2,494	2,494	2,494	2,494
Growth					
Revenue (%)	(12.0)	(37.7)	5.7	10.2	10.2
Operating EBITDA (%)	(50.6)	(44.6)	9.7	12.9	12.4
Operating EBIT (%)	(56.2)	(54.8)	12.5	16.5	15.4
Recurring EPS (%)	(55.6)	(53.7)	14.1	16.8	15.8
Reported EPS (%)	(55.6)	(53.7)	14.1	16.8	15.8
Operating performance					
Gross margin inc. depreciation (%)	32.2	30.8	30.4	31.1	31.8
Gross margin exc. depreciation (%)	37.2	38.9	38.3	38.7	39.0
Operating EBITDA margin (%)	26.9	23.9	24.8	25.4	25.9
Operating EBIT margin (%)	21.8	15.8	16.9	17.8	18.7
Net margin (%)	16.1	12.0	13.0	13.7	14.4
Effective tax rate (%)	22.0	21.5	20.0	20.0	20.0
Dividend payout on recurring profit (%)	114.9	88.7	54.4	47.1	47.5
Interest cover (X)	28.4	25.4	58.7	72.9	109.0
Inventory days	12.3	17.0	15.1	14.9	14.9
Debtor days	49.3	37.0	24.7	22.4	20.4
Creditor days	41.0	67.9	67.4	66.6	66.5
Operating ROIC (%)	21.4	10.9	13.3	15.7	18.2
ROIC (%)	21.0	10.9	13.3	15.6	18.1
ROE (%)	23.9	11.2	12.4	13.6	14.6
ROA (%)	14.2	8.2	9.7	10.7	11.4
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Cash patient revenue	9,372	7,976	8,467	9,292	10,197
SSO patient revenue	3,371	3,850	3,926	4,367	4,858
NHSO patient revenue	6,084	(97)	0	0	0

Sources: Bangkok Chain Hospital; FSSIA estimates

# **Financial Statements**

Bangkok Chain Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	3,039	1,406	1,605	1,875	2,171
Depreciation	950	944	982	1,032	1,088
Associates & minorities	-	-	-	-	
Other non-cash items	24	114	117	136	150
Change in working capital	1,459	1,563	35	41	46
Cash flow from operations	5,471	4,027	2,739	3,084	3,455
Capex - maintenance Capex - new investment	(984)	(896)	(861)	(956)	(1,054)
let acquisitions & disposals	2	4	0	0	(
Other investments (net)	-	-	-	-	
Cash flow from investing	(982)	(892)	(861)	(956)	(1,054)
Dividends paid	(3,491)	(1,247)	(873)	(883)	(1,031)
Equity finance	0	Ó	0	0	( ,,,,,,,,
Debt finance	(3,153)	(2,310)	(200)	0	C
Other financing cash flows	(462)	(32)	(68)	(75)	(82
Cash flow from financing	(7,106)	(3,590)	(1,141)	(958)	(1,113
Non-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	(
let other adjustments	0	0	0	0	(
Movement in cash	(2,616)	(455)	737	1,170	1,288
Free cash flow to firm (FCFF)	4,645.31	3,230.18	1,930.51	2,182.99	2,456.76
ree cash flow to equity (FCFE)	875.07	791.94	1,610.17	2,052.95	2,319.22
Per share (THB)					
FCFF per share	1.86	1.30	0.77	0.88	0.99
FCFE per share	0.35	0.32	0.65	0.82	0.93
Recurring cash flow per share	1.61	0.99	1.08	1.22	1.37
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
, , ,					
Fangible fixed assets (gross)	20,274	20,884	21,751	22,707	23,761
_ess: Accumulated depreciation  Fangible fixed assets (net)	(7,992) <b>12,282</b>	(8,639) <b>12,244</b>	(9,621) <b>12,130</b>	(10,654) <b>12,054</b>	(11,742 <u>)</u> <b>12,02</b> 0
ntangible fixed assets (net)	425	440	440	440	12,020
ong-term financial assets	720	-	-	-	
nvest. in associates & subsidiaries	32	28	28	28	28
Cash & equivalents	2,640	2,185	2,922	4,093	5,38
VC receivable	1,539	839	839	839	839
nventories	362	306	326	357	39
Other current assets	2,294	1,513	1,598	1,761	1,94
Current assets	6,835	4,843	5,686	7,050	8,55
Other assets	223	176	176	176	176
Total assets	19,796	17,731	18,460	19,748	21,210
Common equity	12,445	12,594	13,326	14,318	15,458
Minorities etc.	1,065	1,110	1,166	1,227	1,29
Total shareholders' equity	13,510	13,704	14,492	15,545	16,75
ong term debt	3,888	1,497	1,297	1,297	1,297
Other long-term liabilities	163	187	187	187	18
ong-term liabilities	4,051	1,684	1,484	1,484	1,48
VC payable	1,300	1,368	1,458	1,597	1,75
Short term debt	0	81	81	81	8
Other current liabilities	935	894	944	1,041	1,14
Current liabilities	2,235	2,342	2,483	2,718	2,97
Total liabilities and shareholders' equity	19,796	17,731	18,460	19,748	21,210
Net working capital	1,959	396	361	320	27
nvested capital Includes convertibles and preferred stock which is bei	14,921	13,284	13,135	13,018	12,93
includes convertibles and preferred stock which is ber	ng treated as debt				
er share (THB)					
ook value per share	4.99	5.05	5.34	5.74	6.2
angible book value per share	4.82	4.87	5.17	5.57	6.02
Financial strength					
Net debt/equity (%)	9.2	(4.4)	(10.7)	(17.5)	(23.9
Net debt/total assets (%)	6.3	(3.4)	(8.4)	(13.7)	(18.9
Current ratio (x)	3.1	2.1	2.3	2.6	2.9
CF interest cover (x)	6.9	11.3	44.0	59.8	87.3
<b>a</b> luation	2022	2023	2024E	2025E	2026
Recurring P/E (x) *	12.6	27.3	23.9	20.5	17.
Recurring P/E @ target price (x) *	18.1	39.0	34.2	29.3	25.
Reported P/E (x)	12.6	27.3	23.9	20.5	17.
ividend yield (%)	9.1	3.2	2.3	2.3	2.
rice/book (x)	3.1	3.0	2.9	2.7	2.
Price/tangible book (x)	3.2	3.2	3.0	2.8	2.
V/EBITDA (x) **	8.0	13.9	12.4	10.6	9.
V/EBITDA (x)	11.3	19.8	17.7	15.4	13.
EV/invested capital (x)	2.7	2.9	2.9	2.8	2.
:v/mvested capital (x)					

Sources: Bangkok Chain Hospital; FSSIA estimates

# **Bangkok Chain Hospital PCL (BCH TB)**

FSSIA ESG rating

# **Exhibit 2: FSSIA ESG score implication**

39.71 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

# Exhibit 3: ESG – peer comparison

	FSSIA			Domes	stic ratings	;				Glo	bal ratings			Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Υ	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

# Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.56	0.71	0.75	0.72	0.80	0.85	2.36	3.52
BESG environmental pillar score	0.00	0.00	0.00	0.00	0.38	0.38	2.96	4.63
BESG social pillar score	0.00	0.22	0.22	0.22	0.22	0.22	1.70	3.47
BESG governance pillar score	2.35	2.41	2.62	2.50	2.41	2.63	3.19	2.91
ESG disclosure score	18.06	19.81	19.81	19.81	20.08	20.08	31.27	47.60
Environmental disclosure score	0.00	0.42	0.42	0.42	1.24	1.24	20.57	46.18
Social disclosure score	3.17	10.52	10.52	10.52	10.52	10.52	18.53	41.96
Governance disclosure score	50.87	48.37	48.37	48.37	48.37	48.37	54.64	54.64
Environmental								
Emissions reduction initiatives	No	No	No	No	Yes	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	No	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	_	_	_	_	1	2
GHG scope 2 location-based	_	_	_	_	_	_	5	6
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	Yes						
Total energy consumption	_	_	_	_	_	_	10	12
Renewable energy use	_	_	_	_	_	_	_	_
Electricity used	_	_	_	_	_	_	10	12
Fuel used - natural gas	_	_	_	_	_	_	_	_

 $Sources: Bloomberg; FSSIA's \ compilation$ 

**Exhibit 5: ESG score by Bloomberg** (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 202
Fuel used - crude oil/diesel	No	N						
Waste reduction policy	No	No	No	No	Yes	Yes	Yes	Ye
Hazardous waste	_	_	_	_	_	_	_	
Total waste	_	_	_	_	_	_	_	
Waste recycled	_	_	_	_	_	_	_	
Waste sent to landfills	_	_	_	_	_	_	_	
Environmental supply chain management	No	Ye						
Water policy	No	No	No	No	No	No	Yes	Υe
Water consumption	_	_	_	_	_	_	_	-
Social								
Human rights policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Υe
Policy against child labor	No	Ye						
Quality assurance and recall policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Consumer data protection policy	No	N						
Equal opportunity policy	Yes	Ye						
Gender pay gap breakout	No	N						
Pct women in workforce	_	_	_	_	_	_	_	7
Pct disabled in workforce	_	_	_	_	_	_	_	
Business ethics policy	Yes	Ye						
Anti-bribery ethics policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Health and safety policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Lost time incident rate - employees	_	_	_	_	_	_	0	
Total recordable incident rate - employees	_	_	_	_	_	_	0	
Training policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Fair remuneration policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Number of employees – CSR	_	_	_	_	_	_	8,597	8,87
Employee turnover pct	_	_	_	_	_	_	_	4
Total hours spent by firm - employee training	_	_	_	_	_	_	_	54,70
Social supply chain management	No	Yes	Yes	Yes	Yes	Yes	Yes	Υe
Governance								
Board size	10	10	10	12	12	12	12	1
No. of independent directors (ID)	4	4	4	4	4	4	4	
No. of women on board	3	3	3	4	4	3	3	
No. of non-executive directors on board	5	5	5	5	5	5	5	
Company conducts board evaluations	Yes	Υe						
No. of board meetings for the year	6	5	6	5	5	6	6	
Board meeting attendance pct	93	94	90	96	100	99	94	Ş
Board duration (years)	_	_	_	_	_	_	_	-
Director share ownership guidelines	No	N						
Age of the youngest director	28	29	30	29	30	31	32	3
Age of the oldest director	72	73	74	75	76	77	78	7
No. of executives / company managers	5	5	5	5	5	7	7	
No. of female executives	1	_	_	_	_	_	_	-
Executive share ownership guidelines	No	N						
Size of audit committee	3	3	3	3	3	3	3	
No. of ID on audit committee	3	3	3	3	3	3	3	
Audit committee meetings	4	4	5	5	5	5	5	
Audit meeting attendance %	100	92	100	93	100	100	93	10
Size of compensation committee	0	0	0	0	0	0	0	
No. of ID on compensation committee	_	_	_	_	_	_	_	-
No. of compensation committee meetings	_	_	_	_	_	_	_	
Compensation meeting attendance %	_	_	_	_	_	_	_	
Size of nomination committee	0	0	0	0	0	0	0	
No. of nomination committee meetings	_	_	_	_	_	_	_	
Nomination meeting attendance %	_	_	_	_	_	_	_	
Sustainability governance								
Verification type	No	N						

Sources: Bloomberg; FSSIA's compilation

# **Disclaimer for ESG scoring**

ESG score	Methodolog	ıv			Rating							
		-	transparent rules ha	d component colection		nd invitod to t	ho appual COD C	Slobal Carra	ato.			
The Dow Jones Sustainability	process base	ed on the com	transparent, rules-baseo panies' Total Sustainab al Corporate Sustainabi	ility Scores resulting	Sustainability A	ssessment (C	he annual S&P 0 SA) for DJSI. Co of the S&P Glob	mpanies with	an S&P Globa			
ndices ( <u>DJSI</u> ) By S&P Global	Only the top- inclusion.	ranked comp	anies within each indust	ry are selected for	scoring compa selected from t		ified. The constitutiverse.	uents of the D	JSI indices are			
Sustainability nvestment			ility in Environmental an ansparency in Governal	•	To be eligible for <b>THSI</b> inclusion, verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI							
_ist ( <u>THSI</u> )			preemptive criteria, with				The scoring will I					
y The Stock	1) no irregula	ar trading of th	ne board members and	executives; and 2) free			y and materiality.		4) 1 1			
Exchange of Thailand			, and combined holding ualifying criteria include:				from the THSI co D150b); 2) free fl					
(SET)	70%; 2) inde wrongdoing	pendent direct related to CG,	ctors and free float violat , social & environmental earnings in red for > 3 ye	ion; 3) executives' impacts; 4) equity in	>0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight maximum, and no cap for number of stocks.							
CG Score	An indicator	of CG strengt	h in sustainable develop with support from the St	ment, measured	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69),							
by Thai Institute of			ts are from the perspect				w 50. Weightings					
Directors	an evaluation	n of operation	s.				nolders (weight 2					
Association (Thai IOD)					stakeholders (2 responsibilities		sure & transpare	ency (15%); ar	id 5) board			
<b>AGM level</b> By Thai			vhich shareholders' right I into business operation				four categories: (80-89), and not		· //			
nvestors	transparent a	and sufficiently	y disclosed. All form imp	ortant elements of two	,	00), 0 .0 u	(00 00), and not		00 20.011 10.			
Association (TIA) with			ents to be evaluated an lures before the meeting	nually. The assessment								
support from		•	meeting (10%). (The first	, , ,,								
he SEC	circulation of s	ufficient informa		ating how voting rights can be								
	and verifiability	; and 3) openne		res the meeting minutes that								
Thai CAC	The core ele	ments of the 0	Checklist include corrupt	tion risk assessment,			ed by a committe					
By Thai Private Sector			ols, and the monitoring is good for three years.	and developing of	•		or granting certific re twelve highly r	,				
Collective	(Companies de	eciding to becon	ne a CAC certified member :		professionalisn			•				
Action Against Corruption			an 18-month deadline to su essment, in place of policy a									
(CAC)	managers and		ablishment of whistleblowing									
<u>Morningstar</u>			sk rating provides an ov				score is the sum		d risk. The			
<u>Sustainalytics</u>	risk is unmar	naged. Sources	of how much of a compa s to be reviewed include cor her media, NGO reports/wel	porate publications and	more risk is un	nanaged, the	higher ESG risk	is scorea.				
	information, co		k, ESG controversies, issue		NEGL	Low	Medium	High	Severe			
EC Pook				hat are better	0-10	10-20	20-30 ated as a weight	30-40	40+			
ESG Book	positioned to the principle helps explair over-weighting	outperform o of financial m n future risk-ad	sustainable companies to truer the long term. The nateriality including information of diusted performance. Mathin the the higher materiality and the higher materiality and the basis.	nethodology considers nation that significantly ateriality is applied by	scores using m	ateriality-base	ated as a weight ad weights. The s adicating better p	core is scaled				
MSCI				nanagement of financially their exposure to ESG ris					nethodology to			
	AAA	8.571-10.00	Leader:	leading its industry in m	anaging the most s	gnificant ESG ris	sks and opportunitie	es				
	AA	7.143-8.570	)	J,	5 5		11					
	Α	5.714-7.142		a mixed or unavcention	al track record of	anaging the man	t significant ESC ==	eke and appart	nities relative to			
	BBB	4.286-5.713	Average:	a mixed or unexceptional industry peers	ai ilauk lecord of m	anaging the mos	n agriilicant ESG fis	sks and opportu	nues relative to			
	ВВ	2.857-4.285	5	•								
		1.429-2.856	3			ura and failura to	n manage significan	nt ESG risks				
	В		Laggard:	lagging its industry base	ed on its high expos	ure and failure it						
	B CCC	0.000-1.428	Laggard:	lagging its industry base	ed on its high expos	ure and failure to	o manage eigninean					
	Moody's ass	0.000-1.428 esses the deg a company ir	gree to which companies	s take into account ESG o	bjectives in the d	efinition and ir	mplementation of					
Refinitiv ESG	Moody's ass believes that create susta Designed to based on pu	0.000-1.428 esses the deg a company ir inable value for transparently blicly available	gree to which companies pree to which companies ntegrating ESG factors in or shareholders over the and objectively measure and auditable data. Th	s take into account ESG o	bjectives in the of relatively outped G performance, 100 on relative E	efinition and ir rforming its pe commitment a SG performan	mplementation of eers is better pos nd effectiveness ace and insufficie	across 10 mand degree of to	jate risks and in themes,			
Refinitiv ESG rating	Moody's ass believes that create susta Designed to based on pu reporting ma	0.000-1.428 esses the deg a company ir inable value fo transparently blicly available terial ESG da bbal ESG Sco	gree to which companies pree to which companies to shareholders over the and objectively measure and auditable data. The ta publicly. (Score ratings re is a relative score me	s take into account ESG onto its business model and medium to long term. e a company's relative ES se score ranges from 0 to	bjectives in the of directively outped G performance, 100 on relative E = satisfactory; >50 to ormance on and	efinition and in rforming its percommitment a SG performan o 75 = good; and management	mplementation of eers is better pos and effectiveness ice and insufficied >75 to 100 = exce	across 10 mail across 10 mail nt degree of to	gate risks and in themes, ransparency ir			
Moody's ESG solutions  Refinitiv ESG rating  S&P Global  Bloomberg	Moody's ass believes that create susta Designed to based on pu reporting ma	0.000-1.428 esses the deg a company ir inable value fo transparently blicly available terial ESG da bbal ESG Sco	gree to which companies the grating ESG factors in or shareholders over the and objectively measure and auditable data. The publicly. (Score ratings re is a relative score mean the same industry classification) Bloomberg score evall score is based on Bloomberg.	s take into account ESG onto its business model and medium to long term.  e a company's relative ES are score ranges from 0 to are 0 to 25 = poor; >25 to 50 are sasuring a company's perfections.	bjectives in the of drelatively outped G performance, 100 on relative E = satisfactory; >50 to ormance on and ges from 0 to 10 regated Environmencial materiality.	efinition and informing its percommitment a SG performan or 75 = good; and management b.  nental, Social The score is a	mplementation of the size is better poson and effectiveness note and insufficiend >75 to 100 = excessor ESG risks, opposed and Governance a weighted general size is set to the size in the size is set to	across 10 mant degree of to the state of the	in themes, cansparency in d impacts mance. The power mean)			

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

#### **GENERAL DISCLAIMER**

## ANALYST(S) CERTIFICATION

## Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

#### History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
06-Oct-2021	BUY	28.50	03-May-2023	BUY	23.50	30-Jan-2024	BUY	26.00
25-Oct-2022	BUY	26.00	03-Aug-2023	BUY	22.50	29-Apr-2024	BUY	25.00
09-Feb-2023	BUY	25.50	03-Nov-2023	BUY	24.50	30-Jul-2024	BUY	22.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Chain Hospital	всн тв	THB 15.40	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.

Source: FSSIA estimates

#### **Additional Disclosures**

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 28-Aug-2024 unless otherwise stated.

#### RECOMMENDATION STRUCTURE

#### Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

## **Industry Recommendations**

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.